Maxadilan TFA |
カタログ番号GC81559
One-Click Copy Product Info
|
Maxadilan TFA is a specific irreversible PAC1 receptor agonist and a potent vasodilator peptide present in the salivary glands of sand flies.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
In Vivo, Maxadilan (0.137 mg/kg, i.p., 3 times a week) TFA reduces atherosclerosis in the aortic arch and brachiocephalic trunk of ApoE−/− mice under SC and CED with preserved or further enhanced hypercholesterolemia[1]. Maxadilan (0.137 mg/kg, i.p., once, 0-90 min) TFA increases blood sugar in NIH mice[4]. Maxadilan (0.172-0.343 mg/kg, i.p., once a day, 21 days) TFA increases body weight, reduces basal blood sugar, and promotes the increase of plasma insulin in NIH mice[4]. Maxadilan (0.5-10 μg, i.p., once) TFA reduces LPS -induced mortality in BALB/c mice[5]. Maxadilan (3 μg, i.p., once) TFA inhibits serum levels of TNF-4 while elevates IL-6 and IL-10 levels and prevents LPS-induced thrombocytopenia in LPS-induced BALB/c mice[5].
In Vitro, Maxadilan (20-200 nM, 24 h) TFA enhances the proliferation and migration of human adipose-derived stem cells (hADSCs), and enhances cytokine-induced neural redifferentiation of hADSCs into functional neurons[2]. Maxadilan (80 nM, 24-48 h) TFA decreases the ratio of apoptosis with serum withdrawal treatment in hADSCs through PAC1R ligand-dependent activity mediated by the PKA signaling pathway and PAC1R dimer-dependent activity mediated by the Wnt/β-catenin signaling pathway[2]. Maxadilan (80 nM, 1-3 days) TFA induces an efficient differentiation of hADSCs into neural-like cell morphology in chemical neural induction medium[2]. Maxadilan (5-100 ng/mL) TFA induces human neutrophil chemotaxis[3]. Maxadilan (134 nM, 30 min) TFA increases arteriolar dilation, associated with plasma leakage and leukocyte accumulation in one hamster cheek pouch[3].
References:
[1]. Mey L, et al. PAC1 Agonist Maxadilan Reduces Atherosclerotic Lesions in Hypercholesterolemic ApoE-Deficient Mice. Int J Mol Sci. 2024 Dec 10;25(24):13245.
[2]. Guo X, et al.PAC1R agonist maxadilan enhances hADSC viability and neural differentiation potential. J Cell Mol Med. 2016 May;20(5):874-90.
[3]. Svensjö E, et al.Maxadilan, the Lutzomyia longipalpis vasodilator, drives plasma leakage via PAC1-CXCR1/2-pathway. Microvasc Res. 2012 Mar;83(2):185-93.
[4]..Yu R, et al. Long-term administration of maxadilan improves glucose tolerance and insulin sensitivity in mice. Peptides. 2008 Aug;29(8):1347-53.
[5]. Bozza M, S et al The PACAP-type I receptor agonist maxadilan from sand fly saliva protects mice against lethal endotoxemia by a mechanism partially dependent on IL-10. Eur J Immunol. 1998 Oct;28(10):3120-7.
| Cas No. | SDF | ||
| Formula | C291H466N86O94S6·xC2HF3O2 | M.Wt | 6865.72 |
| 溶解度 | DMSO: 100 mg/mL (Need ultrasonic) | Storage | Store at -20°C |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 145.7 μL | 728.3 μL | 1.4565 mL |
| 5 mM | 29.1 μL | 145.7 μL | 291.3 μL |
| 10 mM | 14.6 μL | 72.8 μL | 145.7 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >96.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)